Clinical trial

Neoadjuvant SNF Precision Therapy Phase III

NCT06913777

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2025-04-08

PhasePHASE3

Study timeline

Study start (actual)2025-04-08Date precision: day

Registry last updated2025-06-06

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Neoadjuvant Therapyunresolved

Interventions

Targeted therapy agents: SNF2 -adebrelimab + famitinib; SNF3 -fluzoparib; SNF4 -apatinibDRUG

Chemotherapy (wP-EC)DRUG

Sponsors & collaborators

Fudan Universitylead sponsor

Mapped research locations

ShanghaiShanghai Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06913777 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.